{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:37:32Z","timestamp":1795034252494,"version":"4.10.2"},"reference-count":142,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022084","name":"Peter MacCallum Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.eururo.2025.03.003","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T22:26:15Z","timestamp":1743287175000},"page":"654-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment"],"prefix":"10.1016","volume":"87","author":[{"given":"Elio","family":"Mazzone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Cannoletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Stabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon L.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.03.003_b0005","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0010","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41585-024-00913-8","article-title":"Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer","volume":"21","author":"Eapen","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0015","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0020","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.03.003_b0025","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","article-title":"Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Zhou","year":"2019","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.eururo.2025.03.003_b0030","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2967\/jnumed.123.266742","article-title":"The value of (68)Ga-PSMA PET\/MRI for classifying patients with PI-RADS 3 lesions on multiparametric MRI: a prospective single-center study","volume":"65","author":"Shi","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.09.003","article-title":"European Association of Nuclear Medicine Focus 5: consensus on molecular imaging and theranostics in prostate cancer","volume":"85","author":"Oprea-Lager","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2022.10.024","article-title":"Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent prostate cancer","volume":"83","author":"Bukavina","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0050","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0055","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","article-title":"Diagnostic performance of prostate-specific membrane antigen positron emission tomography-targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis","volume":"5","author":"Kawada","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0060","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68ga\u2013prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","volume":"5","author":"Stabile","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.eururo.2025.03.003_b0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0085","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2025.03.003_b0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/ebm.6.6.164","article-title":"Which methods for bedside Bayes?","volume":"6","author":"Glasziou","year":"2001","journal-title":"Evid Based Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0100","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots","volume":"74","author":"Cleveland","year":"1979","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.eururo.2025.03.003_b0105","first-page":"1015","article-title":"Fluorine-18\u2013labelled prostate-specific membrane antigen positron emission tomography\/computed tomography or magnetic resonance imaging to diagnose and localise prostate cancer. A Prospective Single-arm Paired Comparison (PEDAL). Eur","volume":"7","author":"Wong","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0110","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00259-020-04863-2","article-title":"68Ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study","volume":"48","author":"Le","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0115","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00259-021-05261-y","article-title":"Diagnostic performance of 68Ga-PSMA-11 PET\/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study","volume":"48","author":"Ferraro","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0120","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00259-023-06142-2","article-title":"A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET\/CT imaging in suspicious prostate cancer","volume":"50","author":"Gao","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41391-023-00782-z","article-title":"Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision","volume":"27","author":"Guo","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2025.03.003_b0130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/pros.24230","article-title":"Comparison between 18F-DCFPyL PET and MRI for the detection of transition zone prostate cancer","volume":"81","author":"Liu","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.03.003_b0135","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.euf.2020.03.004","article-title":"Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography in primary prostate cancer diagnosis","volume":"7","author":"Lopci","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.03.003_b0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1148\/radiol.2021204093","article-title":"Diagnostic performance of 68Ga prostate-specific membrane antigen PET\/MRI compared with multiparametric MRI for detecting clinically significant prostate cancer","volume":"301","author":"Margel","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2025.03.003_b0145","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1007\/s00259-021-05355-7","article-title":"Detection of clinically significant prostate cancer with 18F-DCFPyL PET\/multiparametric MR","volume":"48","author":"Metser","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0150","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4081\/aiua.2022.3.274","article-title":"Targeted prostate biopsy: 68Ga-PSMA PET\/CT vs. mpMRI in the diagnosis of prostate cancer","volume":"94","author":"Pepe","year":"2022","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.eururo.2025.03.003_b0155","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/RLU.0000000000004430","article-title":"Comparison of 18F-PSMA-1007 PET\/CT with 68Ga-PSMA-11 PET\/CT for initial staging in intermediate-and high-risk prostate cancer","volume":"48","author":"Chandekar","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-017-1333-2","article-title":"Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer","volume":"15","author":"Zhang","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0165","doi-asserted-by":"crossref","first-page":"494.e1","DOI":"10.1016\/j.urolonc.2020.10.074","article-title":"Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens","volume":"39","author":"Corona-Montes","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0170","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5489\/cuaj.7739","article-title":"68Ga-prostate-specific membrane antigen positron emission tomography\/computed tomography for patients with favorable intermediate-risk prostate cancer","volume":"16","author":"Dekalo","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2025.03.003_b0175","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41391-021-00347-y","article-title":"Preoperative 68Ga-PSMA PET\/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection","volume":"24","author":"Dekalo","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2025.03.003_b0180","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13014-016-0646-2","article-title":"Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study","volume":"11","author":"Dewes","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0185","doi-asserted-by":"crossref","first-page":"6.e1","DOI":"10.1016\/j.urolonc.2021.07.006","article-title":"How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography \/ computed tomography (68Ga-PSMA PET\/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer?","volume":"40","author":"Erdem","year":"2022","journal-title":"A study of patient. Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0190","doi-asserted-by":"crossref","first-page":"E422","DOI":"10.1097\/RLU.0000000000002289","article-title":"68Ga-PSMA-11 PET\/CT in newly diagnosed prostate adenocarcinoma","volume":"43","author":"Erg\u00fcl","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0195","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.euf.2021.01.004","article-title":"68Ga-PSMA-11 positron emission tomography\/computed tomography for primary lymph node staging before radical prostatectomy: central review of imaging and comparison with histopathology of extended lymphadenectomy","volume":"7","author":"Esen","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.03.003_b0200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bju.15134","article-title":"Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68Ga-PSMA PET\/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer","volume":"127","author":"Franklin","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.003_b0205","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1007\/s00261-020-02640-1","article-title":"A comparison between 68Ga-labeled prostate-specific membrane antigen-PET\/CT and multiparametric MRI for excluding regional metastases prior to radical prostatectomy","volume":"45","author":"Frumer","year":"2020","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.eururo.2025.03.003_b0210","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/JU.0000000000001596","volume":"205","author":"Amiel","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0215","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2022.06.002","volume":"82","author":"Gandaglia","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0220","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2214\/AJR.19.22042","article-title":"Prospective evaluation of (18)F-DCFPyL PET\/CT in detection of high-risk localized prostate cancer: comparison with mpMRI","volume":"215","author":"Gaur","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.eururo.2025.03.003_b0225","first-page":"1659","article-title":"Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer","volume":"63","author":"Gondoputro","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0230","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.juro.2017.07.070","article-title":"Prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography\/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study","volume":"199","author":"Gorin","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0235","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/1078-0432.CCR-18-0768","article-title":"PSMA ligand PET\/MRI for primary prostate cancer: staging performance and clinical impact","volume":"24","author":"Grubmuller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.03.003_b0240","first-page":"58","article-title":"The role of 68GA-PSMA PET\/CT scan in patients with prostate adenocarcinoma who underwent radical prostatectomy","volume":"18","author":"Gultekin","year":"2021","journal-title":"Urol J"},{"key":"10.1016\/j.eururo.2025.03.003_b0245","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/wjnm.WJNM_79_17","article-title":"Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography\/computed tomography: a first-stop-shop","volume":"17","author":"Gupta","year":"2018","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0250","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/1450-1147.207272","article-title":"A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: an initial experience","volume":"16","author":"Gupta","year":"2017","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0255","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.2967\/jnumed.122.265205","article-title":"The diagnostic value of PSMA PET\/CT in men with newly diagnosed unfavorable intermediate-risk prostate cancer","volume":"64","author":"Hagens","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0260","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2967\/jnumed.121.263139","article-title":"Reproducibility of PSMA PET\/CT imaging for primary staging of treatment-na\u00efve prostate cancer patients depends on the applied radiotracer: a retrospective study","volume":"63","author":"Hagens","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0265","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.acra.2020.07.011","article-title":"Comparing the diagnostic performance of multiparametric prostate MRI versus 68Ga-PSMA PET-CT in the evaluation lymph node involvement and extraprostatic extension","volume":"29","author":"Arslan","year":"2022","journal-title":"Acad Radiol"},{"key":"10.1016\/j.eururo.2025.03.003_b0270","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1007\/s00259-022-05827-4","article-title":"Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography\/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection","volume":"49","author":"Hermsen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0275","doi-asserted-by":"crossref","first-page":"540","DOI":"10.2967\/jnumed.119.232199","article-title":"Prostate-specific membrane antigen PET\/CT combined with sentinel node biopsy for primary lymph node staging in prostate cancer","volume":"61","author":"Hinsenveld","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0280","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s11307-018-1278-8","article-title":"[68Ga]PSMA PET\/CT improves initial staging and management plan of patients with high-risk prostate cancer","volume":"21","author":"Hirmas","year":"2019","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.eururo.2025.03.003_b0285","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13550-020-00723-0","article-title":"[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study","volume":"10","author":"Hober\u00fcck","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.eururo.2025.03.003_b0290","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.3390\/jcm11175064","article-title":"Primary staging of prostate cancer patients with [18F]PSMA-1007 PET\/CT compared with [68Ga]Ga-PSMA-11 PET\/CT","volume":"11","author":"Hoffmann","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0295","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.2967\/jnumed.123.265916","article-title":"Do bone scans overstage disease compared with PSMA PET at initial staging? An international multicenter retrospective study with masked independent readers","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0300","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0305","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/ajco.12872","article-title":"68Ga-PSMA-PET\/CT staging prior to definitive radiation treatment for prostate cancer","volume":"14","author":"Hruby","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13550-022-00918-7","article-title":"Assessing the accuracy of [18F]PSMA-1007 PET\/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients","volume":"12","author":"Ingvar","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.eururo.2025.03.003_b0315","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00259-020-04974-w","article-title":"Pelvic lymph-node staging with (18)F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer\u2014the SALT trial","volume":"48","author":"Jansen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0320","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/pros.24231","article-title":"The role of histopathological and biochemical parameters for predicting metastatic disease on 68Ga-PSMA-11 PET in prostate cancer","volume":"81","author":"Aydos","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.03.003_b0325","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00345-019-03066-1","article-title":"Simultaneous whole-body PET\/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer","volume":"38","author":"Kaufmann","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0330","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2967\/jnumed.122.265371","article-title":"Staging prostate cancer with 68Ga-PSMA-11 PET\/CT in the elderly: is preimaging biopsy imperative?","volume":"64","author":"Kesler","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0335","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00259-021-05655-y","article-title":"Staging 68 Ga-PSMA PET\/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement","volume":"49","author":"Kesler","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0340","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00259-023-06585-7","article-title":"Combination of [18F]FDG and [18F]PSMA-1007 PET\/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer","volume":"51","author":"Kim","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0345","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2967\/jnumed.120.245605","article-title":"68Ga-PSMA PET\/CT for primary lymph node and distant metastasis NM staging of high-risk prostate cancer","volume":"62","author":"Klingenberg","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0350","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2967\/jnumed.118.211086","article-title":"68 Ga-PSMA-11 PET\/CT in primary and recurrent prostate carcinoma: Implications for radiotherapeutic management in 121 patients","volume":"60","author":"Koerber","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0355","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000515651","article-title":"68Ga-prostate-specific membrane antigen positron emission tomography-computed tomography-based primary staging and histological correlation after extended pelvic lymph node dissection in intermediate-risk prostate cancer","volume":"106","author":"Kopp","year":"2022","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2025.03.003_b0360","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s00345-020-03131-0","article-title":"68Ga-PSMA PET\/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy","volume":"38","author":"Kopp","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0365","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2967\/jnumed.119.234906","article-title":"Histologically confirmed diagnostic efficacy of 18F-rhPSMA-7 PET for N-staging of patients with primary high-risk prostate cancer","volume":"61","author":"Kroenke","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0370","doi-asserted-by":"crossref","first-page":"408.e19","DOI":"10.1016\/j.urolonc.2022.06.004","article-title":"Significance of metabolic tumor volume and total lesion uptake measured using Ga-68 labelled prostate-specific membrane antigen PET\/CT in primary staging of prostate cancer","volume":"40","author":"Kubilay","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0375","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41391-021-00452-y","article-title":"Preoperative PSMA-PET\/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection","volume":"25","author":"Baas","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2025.03.003_b0380","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MNM.0000000000001110","article-title":"In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?","volume":"41","author":"Kulkarni","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2025.03.003_b0385","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.121.263440","article-title":"Utility of 18F-rhPSMA-7.3 PET for imaging of primary prostate cancer and preoperative efficacy in N-staging of unfavorable intermediate- to very high-risk patients validated by histopathology","volume":"63","author":"Langbein","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0390","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2020.08.012","article-title":"Prostate-specific membrane antigen positron emission tomography\/computed tomography compared with conventional imaging for initial staging of treatment-na\u00efve intermediate- and high-risk prostate cancer: a retrospective single-center study","volume":"5","author":"Lenis","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0395","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1007\/s00259-018-4037-9","article-title":"68Ga-PSMA-617 PET\/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients","volume":"45","author":"Liu","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0400","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.euros.2023.12.001","article-title":"The probability of metastases within different prostate-specific antigen ranges using prostate-specific membrane antigen positron emission tomography in patients with newly diagnosed prostate cancer","volume":"59","author":"Luining","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.03.003_b0405","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00259-023-06464-1","article-title":"A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET\/CT imaging","volume":"51","author":"Lv","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0410","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1007\/s00259-021-05428-7","article-title":"Response to the letter to the editor: Prospective comparison of 18F-PSMA-1007 PET\/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer","volume":"48","author":"Malaspina","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0415","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/biomedicines10040882","article-title":"68Ga-PSMA-11 PET\/CT initial staging in black and white South African males with ISUP grade group 1 and 2 prostate adenocarcinoma","volume":"10","author":"Maserumule","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.eururo.2025.03.003_b0420","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0425","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JU.0000000000001592","article-title":"The predictive value of preoperative negative prostate specific membrane antigen positron emission tomography imaging for lymph node metastatic prostate cancer","volume":"205","author":"Meijer","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0430","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/JU.0000000000003850","article-title":"Intraductal prostate cancer affinity for lymphatic-predominant metastases through 18F-DCFPyL prostate-specific membrane antigen positron emission tomography\/CT scans in pretreatment prostate cancer patients","volume":"211","author":"Bernardino","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0435","doi-asserted-by":"crossref","first-page":"10727","DOI":"10.1038\/s41598-019-46386-3","article-title":"Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging: comparison to 68 Ga-PSMA PET-CT","volume":"9","author":"Mei\u00dfner","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2025.03.003_b0440","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/MNM.0000000000000738","article-title":"The role of 68Ga-PSMA-I&T PET\/CT in the pretreatment staging of primary prostate cancer","volume":"38","author":"Meyrick","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2025.03.003_b0445","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.2967\/jnumed.122.263897","article-title":"68Ga-PSMA-11 PET\/MRI in patients with newly diagnosed intermediate- or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment","volume":"63","author":"Moradi","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0450","doi-asserted-by":"crossref","first-page":"104.e17","DOI":"10.1016\/j.urolonc.2021.11.007","article-title":"Accuracy of 68Ga-PSMA PET\/CT for lymph node and bone primary staging in prostate cancer","volume":"40","author":"Moreira","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0455","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00259-023-06278-1","article-title":"Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer","volume":"50","author":"Muehlematter","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0460","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180667","article-title":"(68)Ga-HBEDD PSMA-11 PET\/CT staging prior to radical prostatectomy in prostate cancer patients: diagnostic and predictive value for the biochemical response to surgery","volume":"92","author":"Nandurkar","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.eururo.2025.03.003_b0465","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1007\/s00259-017-3752-y","article-title":"The accuracy of 68Ga-PSMA PET\/CT in primary lymph node staging in high-risk prostate cancer","volume":"44","author":"\u00d6bek","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0470","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s00259-023-06321-1","article-title":"The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [68Ga]Ga-PSMA-11-PET\/CT in high-risk prostate cancer patients treated with definitive radiotherapy","volume":"50","author":"Onal","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0475","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/pros.24142","article-title":"Clinical parameters and nomograms for predicting lymph node metastasis detected with 68Ga-PSMA-PET\/CT in prostate cancer patients candidate to definitive radiotherapy","volume":"81","author":"Onal","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.03.003_b0480","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/ijnm.IJNM_189_19","article-title":"Incremental value of Ga-68 prostate-specific membrane antigen-11 positron-emission tomography\/computed tomography scan for preoperative risk stratification of prostate cancer","volume":"35","author":"Pallavi","year":"2020","journal-title":"Indian J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0485","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bju.15710","article-title":"Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography\/computed tomography is associated with oncological outcomes in patients with prostate cancer","volume":"129","author":"Bodar","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.003_b0490","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.adro.2020.08.014","article-title":"The impact of 18F-DCFPyL PET-CT imaging on initial staging, radiation, and systemic therapy treatment recommendations for veterans with aggressive prostate cancer","volume":"5","author":"Parikh","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0495","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1148\/radiol.2018172232","article-title":"Gallium 68 PSMA-11 PET\/MR imaging in patients with intermediate- or high-risk prostate cancer","volume":"288","author":"Park","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2025.03.003_b0500","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00345-019-02846-z","article-title":"68Ga-PSMA PET\/CT compared with MRI\/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study","volume":"38","author":"Petersen","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0505","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0510","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40644-019-0273-x","article-title":"High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation","volume":"19","author":"Rahman","year":"2019","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0515","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pros.23685","article-title":"Ga-68-PSMA PET\/CT in treatment-na\u00efve patients with prostate cancer: which clinical parameters and risk stratification systems best predict PSMA-positive metastases?","volume":"78","author":"Rogasch","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.03.003_b0520","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00259-017-3852-8","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans","volume":"45","author":"Sathekge","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0525","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2967\/jnumed.123.266495","article-title":"Prostate-specific membrane antigen\u2013targeted radioguided pelvic lymph node dissection in newly diagnosed prostate cancer patients with a suspicion of locoregional lymph node metastases: the DETECT trial","volume":"65","author":"Schilham","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0530","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2967\/jnumed.118.220855","article-title":"Impact of 68Ga-PSMA PET\/CT on the radiotherapeutic approach to prostate cancer in comparison to CT: A retrospective analysis","volume":"60","author":"Schmidt-Hegemann","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0535","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.122.263889","article-title":"Comparison of 68Ga-PSMA-617 PET\/CT and 68Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study","volume":"64","author":"Schollhammer","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0540","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","article-title":"Initial experience of 68Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy","volume":"69","author":"Bud\u00e4us","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0545","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","article-title":"Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET\/CT","volume":"44","author":"Schwenck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0550","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00259-020-04995-5","article-title":"Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET\/CT and its relationship with modified D\u2019Amico risk classification","author":"Simsek","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0555","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00259-015-3188-1","article-title":"68Ga-PSMA-11 PET\/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients","volume":"43","author":"Sterzing","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0560","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE)","volume":"84","author":"Surasi","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0565","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11307-021-01650-9","article-title":"Incremental impact of [68 Ga]Ga-PSMA-11 PET\/CT in primary N and M staging of prostate cancer prior to curative-intent surgery: a prospective clinical trial in comparison with mpMRI","volume":"24","author":"Szigeti","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.eururo.2025.03.003_b0570","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.2967\/jnumed.117.207696","article-title":"One-stop-shop whole-body68Ga-PSMA-11 PET\/MRI compared with clinical nomograms for preoperative T and N staging of high-risk prostate cancer","volume":"59","author":"Thalgott","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0575","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/MNM.0000000000000749","article-title":"Comparison of 68 Ga-PSMA PET\/CT and multiparametric MRI for staging of high-risk prostate cancer 68 Ga-PSMA PET and MRI in prostate cancer","volume":"38","author":"Tulsyan","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2025.03.003_b0580","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/pros.24420","article-title":"Comparison of 68Ga-PSMA PET\/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: a retrospective study","volume":"82","author":"Ucar","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.03.003_b0585","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1148\/radiol.220218","article-title":"18F-DCFPyL PET\/CT for initially diagnosed and biochemically recurrent prostate cancer: prospective trial with pathologic confirmation","volume":"305","author":"Ulaner","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2025.03.003_b0590","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0595","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","article-title":"Potential impact of 68Ga-PSMA-11 PET\/CT on the planning of definitive radiation therapy for prostate cancer","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.03.003_b0600","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JU.0000000000000531","article-title":"Prospective validation of gallium-68 prostate specific membrane antigen-positron emission tomography\/computerized tomography for primary staging of prostate cancer","volume":"203","author":"Van Kalmthout","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0605","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bju.14506","article-title":"Gallium-68-prostate-specific membrane antigen (68Ga-PSMA) positron emission tomography (PET)\/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer","volume":"124","author":"van Leeuwen","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.003_b0610","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bju.13540","article-title":"Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography for preoperative lymph node staging in prostate cancer","volume":"119","author":"van Leeuwen","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.003_b0615","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euo.2023.03.010","article-title":"Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission","volume":"6","author":"Vis","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0620","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s00259-023-06283-4","article-title":"A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET\/CT in patients with primary prostate cancer","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0625","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00259-020-04782-2","article-title":"18F-DCFPyL PET\/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy","volume":"48","author":"Wondergem","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.03.003_b0630","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/1754-9485.12791","article-title":"Comparative study between (68) Ga-prostate-specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer","volume":"62","author":"Wong","year":"2018","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0635","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bju.14828","article-title":"Risk of metastatic disease on 68gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer","volume":"124","author":"Yaxley","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.003_b0640","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/JU.0000000000000053","article-title":"Outcomes of primary lymph node staging of intermediate and high risk prostate cancer with 68Ga-PSMA positron emission tomography\/computerized tomography compared to histological correlation of pelvic lymph node pathology","volume":"201","author":"Yaxley","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0645","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/21681805.2022.2119272","article-title":"The clinical consequences of routine 68Ga-PSMA-11 PET\/CT in patients with newly diagnosed prostate cancer, ISUP grade 5 and no metastases based on standard imaging\u2014preliminary results","volume":"56","author":"Zacho","year":"2022","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0650","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/JU.0000000000004025","volume":"212","author":"Niu","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0655","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euo.2023.08.010","volume":"7","author":"Mazzone","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0660","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0665","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0670","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0675","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41585-018-0140-8","article-title":"Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer","volume":"16","author":"van Leeuwen","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0680","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0685","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0690","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.003_b0695","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.19.02768","article-title":"Molecular biomarkers in localized prostate cancer: ASCO guideline","volume":"38","author":"Eggener","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0700","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2023.11.008","volume":"7","author":"Buteau","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.003_b0705","doi-asserted-by":"crossref","unstructured":"Hofman MS, Kasivisvanathan V, Link E, et al. Baseline nodal status on (68)Ga-PSMA-11 positron emission tomography\/computed tomography in men with intermediate- to high-risk prostate cancer is prognostic for treatment failure: follow-up of the proPSMA trial. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.11.006.","DOI":"10.1016\/j.euo.2024.11.006"},{"key":"10.1016\/j.eururo.2025.03.003_b0710","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T20:31:15Z","timestamp":1762288275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825001551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":142,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0302283825001551"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.03.003","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}